Introduction: Multiple sclerosis (MS) is a CNS autoimmune disease. Depression is more common in patients with multiple sclerosis (MS) than in the general population and significantly impairs quality of life. Since metformin (Met) play a crucial role in development and physiological function of the CNS and reduces inflammation, the effect of Met on the improvement of depression state of MS induced by lysolecithine was studied in rats. Methods and Materials: 40 Wistar rats randomly divided into five groups, sham, Met, MS group, MS group receiving Met and positive control group. The forced swim test and open field were used to investigate Changes in the level of depression. Also, the cerebral concentrations of interleukin-6 (IL-6) and TNF alpha were measured by a special kit. Results: IL-6 and TNF-α in the Met treated group showed a significant reduction compared to the MS group. Behavioral evaluation also showed that Met significantly increased cross line and duration of staying in the central square them in the open field and decreased immobility time in the forced swim test. Conclusion: It seems that treatment with Met is able to prevent relapse of depression. Positive effects of Met may be due to decrements in TNF-α and IL-6 concentrations as pro-inflammatory factor. These results suggest that Met can be used as an effective ingredient in the treatment of MS.